HSD17B1 genetic variants and hormone receptor-defined breast cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 10, 2008, Pages 2766-2772

  Gaudet, Mia M ^a,e   Chanock, Stephen ^a   Dunning, Alison ^b   Driver, Kristy ^b   Brinton, Louise A ^a   Lissowska, Jolanta ^a,c   Peplonska, Beata ^d   Pharoah, Paul ^b   Garcia Closas, Montserrat ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c INSTITUTE OF ONCOLOGY   (Poland)

^d NOFER INSTITUTE OF OCCUPATIONAL MEDICINE   (Poland)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17BETA HYDROXYSTEROID DEHYDROGENASE 1; ESTROGEN RECEPTOR; TESTOSTERONE 17BETA DEHYDROGENASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER RISK; CAUCASIAN; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; INTRON; MAJOR CLINICAL STUDY; MEDICAL LITERATURE; POLAND; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUBLICATION; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

17-HYDROXYSTEROID DEHYDROGENASES; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; GREAT BRITAIN; HAPLOTYPES; HUMANS; LOGISTIC MODELS; POLAND; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 54249096645     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-2891     Document Type: Article

References (23)

1. Thompson PA, Ambrosone C. Molecular epidemiology of genetic polymorphisms in estrogen metabolizing enzymes in human breast cancer. J Natl Cancer Inst Monogr 2000;27:125-34.
2. Vihko P, Harkonen P, Soronen P, et al. 17 beta-hydroxysteroid dehydrogenases - their role in pathophysiology. Mol Cell Endocrinol 2004;215:83-8.
3. Miettinen M, Mustonen M, Poutanen M, et al. 17Beta-hydroxysteroid dehydrogenases in normal human mammary epithelial cells and breast tissue. Breast Cancer Res Treat 1999;57:175-82.
4. Jansson A, Gunnarsson C, Stal O. Proliferative responses to altered 17{beta}-hydroxysteroid dehydrogenase (17HSD) type 2 expression in human breast cancer cells are dependent on endogenous expression of 17HSD type 1 and the oestradiol receptors. Endocr Relat Cancer 2006;13:875-84.
5. Gunnarsson C, Ahnstrom M, Kirschner K, et al. Amplification of HSD17B1 and ERBB2 in primary breast cancer. Oncogene 2003;22:34-40.
6. Oduwole OO, Li Y, Isomaa VV, et al. 17beta-Hydroxysteroid dehydrogenase type 1 is an independent prognostic marker in breast cancer. Cancer Res 2004;64:7604-9.
7. Wu AH, Seow A, Arakawa K, Van Den Berg D, Lee HP, Yu MC. HSD17B1 and CYP17 polymorphisms and breast cancer risk among Chinese women in Singapore. Int J Cancer 2003;104:450-7.
8. Setiawan VW, Hankinson SE, Colditz GA, Hunter DJ, De Vivo I. HSD17B1 gene polymorphisms and risk of endometrial and breast cancer. Cancer Epidemiol Biomarkers Prev 2004;13:213-9.
9. Feigelson HS, McKean-Cowdin R, Coetzee GA, Stram DO, Kolonel LN, Henderson BE. Building a multigenic model of breast cancer susceptibility: CYP17 and HSD17B1 are two important candidates. Cancer Res 2001;61:785-9.
10. Mannermaa A, Peltoketo H, Winqvist R, et al. Human familial and sporadic breast cancer: analysis of the coding regions of the 17 beta-hydroxysteroid dehydrogenase 2 gene (EDH17B2) using a single-strand conformation polymorphism assay. Hum Genet 1994;93:319-24.
11. Justenhoven C, Hamann U, Schubert F, et al. Breast cancer: a candidate gene approach across the estrogen metabolic pathway. Breast Cancer Res Treat 2008;108:137-49.
12. Feigelson HS, Cox DG, Cann HM, et al. Haplotype analysis of the HSD17B1 gene and risk of breast cancer: a comprehensive approach to multicenter analyses of prospective cohort studies. Cancer Res 2006;66:2468-75.
13. Garcia-Closas M, Brinton LA, Lissowska J, et al. Established breast cancer risk factors by clinically important tumour characteristics. Br J Cancer 2006;95:123-9.
14. Cebrian A, Pharoah PD, Ahmed S, et al. Tagging single-nucleotide polymorphisms in antioxidant defense enzymes and susceptibility to breast cancer. Cancer Res 2006;66:1225-33.
15. The National Cancer Institute Breast and Prostate Cancer Cohort Consortium. A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. Nat Rev Cancer 2005;5:977-85.
16. Kraft P, Pharoah P, Chanock SJ, et al. Genetic variation in the HSD17B1 gene and risk of prostate cancer. PLoS Genet 2005;1:e68.
17. Packer BR, Yeager M, Burdett L, et al. SNP500Cancer: a public resource for sequence validation, assay development, and frequency analysis for genetic variation in candidate genes. Nucleic Acids Res 2006;34:D617-21.
18. Sakoda LC, Blackston C, Doherty JA, et al. Polymorphisms in steroid hormone biosynthesis genes and risk of breast cancer and fibrocystic breast conditions in Chinese women. Cancer Epidemiol Biomarkers Prev 2008;17:1066-73.
19. Justenhoven C, Hamann U, Schubert F, et al. Breast cancer: a candidate gene approach across the estrogen metabolic pathway. Breast Cancer Res Treat 2007;108:137-49.
20. Laird NM, Mosteller F. Some statistical methods for combining experimental results. Int J Technol Assess Health Care 1990;6:5-30.
21. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-101.
22. Poole C, Greenland S. Random-effects meta-analyses are not always conservative. Am J Epidemiol 1999;150:469-75.
23. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.